Does Prior Authorization for Tocilizumab Lead to Unacceptable Treatment Delays in Giant Cell Arteritis?

2025/05/15 by Zhuan Jiang, Lillian Barra · 1 voice
Medicine · #Coagulation, Bradykinin, Polyphosphates, and Angioedema #Vasculitis and related conditions

paper · pdf · doi:10.3899/jrheum.2025-0423

openalex publication_date 2025/05/15 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Abstract

Giant cell arteritis (GCA) is a large-vessel vasculitis that affects individuals over the age of 50 and predominantly women in their 70s.¹ The estimated pooled incidence of GCA is approximately 10 per 100,000 persons aged 50 years or older, with a higher incidence of 20-25 per 100,000 seen in Scandinavian countries and other northern countries, including Canada.^2-4

Discussions

• Editorial Does Prior Authorization for Tocilizumab Lead to Unacceptable Treatment Delays in Giant Cell Arteritis? 📖 doi.org/10.3899/jrhe... @westernu.ca #giantcellarteritis #vasculitis [bsky, 1 points, 0 comments]

Related

• Can India end child labour
• Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database
• French protocol for the diagnosis and management of giant cell arteritis
• Association between antibiotic use and the onset of giant cell arteritis and polymyalgia rheumatica: A nested case–control study from E3N‐European Prospective Investigation into Cancer and Nutrition
• A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritis